Volume Alert: Viropharma (VPHM)

Posted in General 
June 4th, 2009

ViroPharma (VPHM) has traded over 270,000 shares in the first 25 minutes since the halt was released.  The company has received a Complete Response letter from the FDA related to its supplemental Biologics License Application for Cinryze as a treatment for acute attacks of hereditary angioedema.   Shares are down almost 8% at $6.40 as of 8:24 AM EST; its 52-week trading range is $3.79 to $15.16.  FULL DATA over at Biohealthinvestor.com.

Jon C. Ogg
June 4, 2009

Comments are closed

-->